Valuation: Avenue Therapeutics, Inc.

Market Cap 12.52L 11.21L 10.35L 9L 17.51L 12Cr 17.79L 1.23Cr 49.24L 6.24Cr 46.99L 45.99L 20Cr P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -16.03L -14.36L -13.25L -11.99L -22.41L -15Cr -22.78L -1.58Cr -63.04L -7.99Cr -60.16L -58.87L -25Cr EV / Sales 2024
-
EV / Sales 2025 -4,91,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day+46.67%
1 week+8.86%
Current month+10.00%
1 month+10.00%
3 months+23.60%
6 months-20.00%
Current year-35.31%
1 week 0.35
Extreme 0.35
0.44
1 month 0.35
Extreme 0.35
0.49
Current year 0.15
Extreme 0.15
0.9
1 year 0.15
Extreme 0.15
0.97
3 years 0.15
Extreme 0.15
26.47
5 years 0.15
Extreme 0.15
2,081.25
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2022
Chief Executive Officer 36 31/03/2022
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 09/02/2015
Director/Board Member 69 01/08/2015
Chairman 68 07/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/26 FreeCompany 1,11,209 3.4934%
31/03/25 FreeCompany 33,724 1.6419%
31/12/24 OtherCompany 2,94,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
+46.67%+8.86%-38.48%-98.46% 12.52L
+0.34%+1.12%+34.75%+61.06% 6.44TCr
-0.20%+2.63%+14.29%+83.54% 5.62TCr
+1.11%+2.37%+15.83%+107.64% 5.42TCr
-1.43%-1.17%+26.27%+52.86% 4.53TCr
-0.48%-2.80%+18.01%+117.99% 4.22TCr
+0.82%+1.37%+227.94%+922.41% 4.08TCr
+0.81%+44.40%+107.56%+91.76% 3.38TCr
-0.26%-2.57%+12.55%+45.18% 3.22TCr
-1.29%-2.88%+21.60%-11.92% 2.36TCr
Average +4.61%+4.05%+44.03%+137.21% 3.93TCr
Weighted average by Cap. +0.02%+3.60%+50.15%+162.29%

Financials

2024 2025
Net sales - 1.4 1.26 1.16 1.05 1.96 133.7 1.99 13.84 5.52 69.97 5.27 5.16 221.62
Net income -1.17Cr -1.04Cr -96.29L -87.13L -1.63Cr -110.96Cr -1.66Cr -11Cr -4.58Cr -58Cr -4.37Cr -4.28Cr -183.92Cr -29.09L -26.06L -24.04L -21.75L -40.68L -28Cr -41.33L -2.87Cr -1.14Cr -14Cr -1.09Cr -1.07Cr -46Cr
Net Debt -25.94L -23.23L -21.44L -19.4L -36.27L -25Cr -36.86L -2.56Cr -1.02Cr -13Cr -97.35L -95.28L -41Cr -28.55L -25.57L -23.59L -21.35L -39.92L -27Cr -40.57L -2.81Cr -1.12Cr -14Cr -1.07Cr -1.05Cr -45Cr
Projected Income Statement - Annual - Avenue Therapeutics, Inc.
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
28/26/28 $0.3800 -4.64% 5,007
27/26/27 $0.3985 -3.34% 2,115
26/26/26 $0.4123 +7.08% 10,999
23/26/23 $0.3850 -4.75% 234

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avenue Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATXI Stock